ClinicalTrials.gg
CompletedNCT00117325Updated Mar 13, 2018Results posted

Study Of Adults And Adolescents With Vasomotor Rhinitis

A Phase 3 interventional study of GW685698X in Rhinitis, Vasomotor, sponsored by GlaxoSmithKline. Completed at 53 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-03-13.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).

02

Conditions studied

  • Rhinitis, Vasomotor

Keywords

  • Vasomotor Rhinitis
  • VMR
  • nonallergic rhinitis
  • GW685698X
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be outpatients.
  • Diagnosis of VMR.
  • Literate in English or native language.

Exclusion criteria

Exclusion criteria:

  • Significant concomitant medical condition.
  • Use or other allergy medications during the study.
  • Used tobacco products within the past year.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
352 participants (actual)

Study arms

  • Experimental
    GW685698X

    GW685698X

    Drug: GW685698X

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Score (rTNSS)

    The daily rTNSS was the average of the AM (morning) and PM (before bed time) rTNSS assessments. Each rTNSS assessment comprised the sum of the three nasal symptom scores for rhinorrhea, nasal congestion and postnasal drip where each symptom was scored on a scale of 0 (no symptoms) to 3 (severe symptoms).. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

    Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4

Secondary outcomes

  1. Mean Change From Baseline Over the Entire Treatment Period in Morning (AM), Pre-dose, Instantaneous Total Nasal Symptom Scores (iTNSS)

    The AM, pre-dose, iTNSS is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). . The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from baseline was calculated as endpoint value minus the baseline value. Baseline visit was 4 days prior to randomization (Day 1).

    Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4

  2. Number of Participants With Overall Evaluation of Response to Therapy

    The overall evaluation of Response to Therapy was based on a 7-point categorical scale where the participants rated their perception of the change or lack of change in their VMR (Vasomotor rhinitis) symptoms at the end of the study. The 7 categories were: 1=significantly improved, 2=moderately improved, 3= mildly improved, 4= no change, 5= mildly worse, 6= moderately worse, and 7= significantly worse.

    Time frame: Up to 4 weeks

  3. Mean Change From Baseline Over the Entire Treatment Period in AM Pre-dose rTNSS

    The rTNSS is a rating of the severity of symptoms over the previous 12 hours and is performed in the AM (AM rTNSS). . The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. Change from Baseline was calculated as post randomization value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

    Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4

  4. Mean Change From Baseline Over the Entire Treatment Period in Evening (PM) rTNSS

    The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The rTNSS is a rating of the severity of symptoms over the previous 12 hours and is performed in the PM (PM rTNSS). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

    Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4

  5. Mean Percent Change From Baseline Over the Entire Treatment Period in Daily rTNSS

    The daily rTNSS was the average of the AM (morning) and PM (before bed time) rTNSS assessments.The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

    Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4

  6. Mean Percent Change From Baseline Over the Entire Treatment Period in AM, Pre-dose iTNSS

    The AM, pre-dose, iTNSS is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

    Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4

  7. Mean Change From Baseline Over the Entire Treatment Period in Individual Daily, Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Post-nasal Drip

    The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The daily reflective nasal symptom scores was the average of the AM (morning) and PM (before bed time) rTNSS assessments. Each rTNSS assessment comprised the sum of the three nasal symptom. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

    Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4

  8. Mean Change From Baseline Over the Entire Treatment Period in Individual AM, Pre-dose, Instantaneous, Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip

    The AM, pre-dose, instantaneous nasal symptom score is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

    Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4

  9. Mean Change From Baseline Over the Entire Treatment Period in Individual AM, Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip

    The reflective nasal symptom score is a rating of the severity of symptoms over the previous 12 hours and is performed in the AM (AM rTNSS). Score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

    Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4

  10. Mean Change From Baseline Over the Entire Treatment Period in Individual PM, Reflective, Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip

    The reflective nasal symptom score is a rating of the severity of symptoms over the previous 12 hours and was performed in the PM (PM rTNSS). Score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

    Time frame: Baseline (4 days prior to randomization [Day 1]) and up to Week 4

  11. Mean Scores Changes From Baseline as a Function of Time

    The onset of treatment effect was assessed by the mean change from Baseline in AM iTNSS (Days 1 to 28), the mean change from Baseline in daily rTNSS (Days 1 to 28), and mean change from Baseline in AM rTNSS and PM rTNSS. The time to maximum effect was also evaluated by the mean change from Baseline in daily rTNSS for Days 1 to 28. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

    Time frame: Baseline (4 days prior to randomization [Day 1]) and Daily for 28 days

07

Results

Posted Mar 13, 2018

Participant flow

The actual dose delivered from the product was 27.5 micrograms (µg) /actuation, which is therefore proposed as the label claim rather than 25 µg/actuation. Based on this spray content assessment, the dose examined in this study was actually 110 µg rather than the 100 µg dose indicated in the protocol.

Participant flow — Overall Study
MilestonePlaceboFluticasone Furoate 110 mcg QD
Started173179
Completed160167
Not completed1312
Withdrew: Adverse event33
Withdrew: Lost to follow-up11
Withdrew: Protocol violation23
Withdrew: Withdrawal by subject32
Withdrew: Lack of efficacy10
Withdrew: Use of prohibited medicine12
Withdrew: Early termination11
Withdrew: Admisnitrative10

Outcome measures

PrimaryMean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Score (rTNSS)

The daily rTNSS was the average of the AM (morning) and PM (before bed time) rTNSS assessments. Each rTNSS assessment comprised the sum of the three nasal symptom scores for rhinorrhea, nasal congestion and postnasal drip where each symptom was scored on a scale of 0 (no symptoms) to 3 (severe symptoms).. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

Time frame:
Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Reported as:
Least squares mean · Score on scale
Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Score (rTNSS)
Score on scalePlaceboFluticasone Furoate 110 mcg QD
Mean Change From Baseline Over the Entire Treatment Period in Daily Reflective Total Nasal Symptom Score (rTNSS)-1.71 ± 0.16-2.05 ± 0.15
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.050 · Mean difference (net): -0.335 · 95% CI -0.67 to 0.00Analysis of covariance (ANCOVA) method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
SecondaryMean Change From Baseline Over the Entire Treatment Period in Morning (AM), Pre-dose, Instantaneous Total Nasal Symptom Scores (iTNSS)

The AM, pre-dose, iTNSS is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). . The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from baseline was calculated as endpoint value minus the baseline value. Baseline visit was 4 days prior to randomization (Day 1).

Time frame:
Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Reported as:
Least squares mean · Score on scale
Mean Change From Baseline Over the Entire Treatment Period in Morning (AM), Pre-dose, Instantaneous Total Nasal Symptom Scores (iTNSS)
Score on scalePlaceboFluticasone Furoate 110 mcg QD
Mean Change From Baseline Over the Entire Treatment Period in Morning (AM), Pre-dose, Instantaneous Total Nasal Symptom Scores (iTNSS)-1.48 ± 0.16-1.87 ± 0.16
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.027 (Week 1-4) · Mean difference (net): -0.393 · 95% CI -0.74 to -0.05ANCOVA method was used adjusting for baseline iTNSS, country, age, and gender, in addition to treatment effect.
SecondaryNumber of Participants With Overall Evaluation of Response to Therapy

The overall evaluation of Response to Therapy was based on a 7-point categorical scale where the participants rated their perception of the change or lack of change in their VMR (Vasomotor rhinitis) symptoms at the end of the study. The 7 categories were: 1=significantly improved, 2=moderately improved, 3= mildly improved, 4= no change, 5= mildly worse, 6= moderately worse, and 7= significantly worse.

Time frame:
Up to 4 weeks
Reported as:
Count of participants · Participants
Number of Participants With Overall Evaluation of Response to Therapy
ParticipantsPlaceboFluticasone Furoate 110 mcg QD
Significantly Improved2633
Moderately Improved3740
Mildly Improved4547
No Change5250
Mildly Worse13
Moderately Worse41
Significantly Worse32
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 mcg QD · Regression, Logistic · p = 0.184logistic regression adjusting for age, gender, investigator, and treatment.
SecondaryMean Change From Baseline Over the Entire Treatment Period in AM Pre-dose rTNSS

The rTNSS is a rating of the severity of symptoms over the previous 12 hours and is performed in the AM (AM rTNSS). . The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. Change from Baseline was calculated as post randomization value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

Time frame:
Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Reported as:
Least squares mean · Score on scale
Mean Change From Baseline Over the Entire Treatment Period in AM Pre-dose rTNSS
Score on scalePlaceboFluticasone Furoate 110 mcg QD
Mean Change From Baseline Over the Entire Treatment Period in AM Pre-dose rTNSS-1.69 ± 0.16-2.04 ± 0.16
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.051 · Mean difference (net): -0.348 · 95% CI -0.70 to 0.00ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
SecondaryMean Change From Baseline Over the Entire Treatment Period in Evening (PM) rTNSS

The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The rTNSS is a rating of the severity of symptoms over the previous 12 hours and is performed in the PM (PM rTNSS). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

Time frame:
Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Reported as:
Least squares mean · Score on scale
Mean Change From Baseline Over the Entire Treatment Period in Evening (PM) rTNSS
Score on scalePlaceboFluticasone Furoate 110 mcg QD
Mean Change From Baseline Over the Entire Treatment Period in Evening (PM) rTNSS-1.77 ± 0.16-2.07 ± 0.15
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.076 · Mean difference (net): -0.304 · 95% CI -0.64 to 0.03ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
SecondaryMean Percent Change From Baseline Over the Entire Treatment Period in Daily rTNSS

The daily rTNSS was the average of the AM (morning) and PM (before bed time) rTNSS assessments.The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

Time frame:
Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Reported as:
Least squares mean · Percent change in score
Mean Percent Change From Baseline Over the Entire Treatment Period in Daily rTNSS
Percent change in scorePlaceboFluticasone Furoate 110 mcg QD
Mean Percent Change From Baseline Over the Entire Treatment Period in Daily rTNSS-26.14 ± 2.45-30.65 ± 2.40
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.093 · Mean difference (net): -4.510 · 95% CI -9.77 to 0.75ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
SecondaryMean Percent Change From Baseline Over the Entire Treatment Period in AM, Pre-dose iTNSS

The AM, pre-dose, iTNSS is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

Time frame:
Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Reported as:
Least squares mean · Percent change in score
Mean Percent Change From Baseline Over the Entire Treatment Period in AM, Pre-dose iTNSS
Percent change in scorePlaceboFluticasone Furoate 110 mcg QD
Mean Percent Change From Baseline Over the Entire Treatment Period in AM, Pre-dose iTNSS-21.09 ± 2.54-27.46 ± 2.50
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.023 · Mean difference (net): -6.372 · 95% CI -11.8 to -0.90ANCOVA method was used adjusting for baseline iTNSS, country, age, and gender, in addition to treatment effect.
SecondaryMean Change From Baseline Over the Entire Treatment Period in Individual Daily, Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Post-nasal Drip

The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3. The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The daily reflective nasal symptom scores was the average of the AM (morning) and PM (before bed time) rTNSS assessments. Each rTNSS assessment comprised the sum of the three nasal symptom. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

Time frame:
Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Reported as:
Least squares mean · Score on scale
Mean Change From Baseline Over the Entire Treatment Period in Individual Daily, Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Post-nasal Drip
Score on scalePlaceboFluticasone Furoate 110 mcg QD
Rhinorrhea-0.50 ± 0.06-0.62 ± 0.06
Nasal Congestion-0.68 ± 0.06-0.81 ± 0.06
Post-nasal Drip-0.51 ± 0.06-0.61 ± 0.06
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.061 · Mean difference (net): -0.118 · 95% CI -0.24 to 0.01ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.061 · Mean difference (net): -0.124 · 95% CI -0.25 to 0.01
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.138 · Mean difference (net): -0.095 · 95% CI -0.22 to 0.03ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
SecondaryMean Change From Baseline Over the Entire Treatment Period in Individual AM, Pre-dose, Instantaneous, Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip

The AM, pre-dose, instantaneous nasal symptom score is the sum of the 3 individual nasal symptom score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

Time frame:
Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Reported as:
Least squares mean · Score on scale
Mean Change From Baseline Over the Entire Treatment Period in Individual AM, Pre-dose, Instantaneous, Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip
Score on scalePlaceboFluticasone Furoate 110 mcg QD
Rhinorrhea-0.44 ± 0.06-0.56 ± 0.06
Nasal congestion-0.54 ± 0.06-0.70 ± 0.06
Post-nasal drip-0.48 ± 0.06-0.60 ± 0.06
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.087 · Mean difference (net): -0.113 · 95% CI -0.24 to 0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.015 · Mean difference (net): -0.164 · 95% CI -0.30 to -0.03ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.106 · Mean difference (net): -0.112 · 95% CI -0.25 to 0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
SecondaryMean Change From Baseline Over the Entire Treatment Period in Individual AM, Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip

The reflective nasal symptom score is a rating of the severity of symptoms over the previous 12 hours and is performed in the AM (AM rTNSS). Score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

Time frame:
Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Reported as:
Least squares mean · Score on scale
Mean Change From Baseline Over the Entire Treatment Period in Individual AM, Reflective Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip
Score on scalePlaceboFluticasone Furoate 110mcg QD
Rhinorrhea-0.48 ± 0.06-0.61 ± 0.06
Nasal congestion-0.65 ± 0.06-0.78 ± 0.06
Post-nasal drip-0.55 ± 0.06-0.64 ± 0.06
Statistical analysis
  • Placebo vs Fluticasone Furoate 110mcg QD · ANCOVA · p = 0.048 · Mean difference (net): -0.132 · 95% CI -0.26 to -0.00ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110mcg QD · ANCOVA · p = 0.076 · Mean difference (net): -0.124 · 95% CI -0.26 to 0.01ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110mcg QD · ANCOVA · p = 0.164 · Mean difference (net): -0.093 · 95% CI -0.22 to 0.04ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
SecondaryMean Change From Baseline Over the Entire Treatment Period in Individual PM, Reflective, Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip

The reflective nasal symptom score is a rating of the severity of symptoms over the previous 12 hours and was performed in the PM (PM rTNSS). Score assessments for rhinorrhea, nasal congestion and postnasal drip performed at the moment immediately prior to taking their dose where each symptom was scored on a scale of 0 to 3 (0= no symptoms, 3= severe symptoms). Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

Time frame:
Baseline (4 days prior to randomization [Day 1]) and up to Week 4
Reported as:
Least squares mean · Score on scale
Mean Change From Baseline Over the Entire Treatment Period in Individual PM, Reflective, Nasal Symptom Scores for Rhinorrhea, Nasal Congestion and Postnasal Drip
Score on scalePlaceboFluticasone Furoate 110 mcg QD
Rhinorrhea-0.53 ± 0.06-0.59 ± 0.06
Nasal congestion-0.73 ± 0.06-0.84 ± 0.06
Post-nasal drip-0.49 ± 0.06-0.59 ± 0.06
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.136 · Mean difference (net): -0.096 · 95% CI -0.22 to 0.03ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.100 · Mean difference (net): -0.111 · 95% CI -0.24 to 0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.100 · Mean difference (net): -0.111 · 95% CI -0.24 to 0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
SecondaryMean Scores Changes From Baseline as a Function of Time

The onset of treatment effect was assessed by the mean change from Baseline in AM iTNSS (Days 1 to 28), the mean change from Baseline in daily rTNSS (Days 1 to 28), and mean change from Baseline in AM rTNSS and PM rTNSS. The time to maximum effect was also evaluated by the mean change from Baseline in daily rTNSS for Days 1 to 28. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was 4 days prior to randomization (Day 1).

Time frame:
Baseline (4 days prior to randomization [Day 1]) and Daily for 28 days
Reported as:
Least squares mean · Score on scale
Mean Scores Changes From Baseline as a Function of Time
Score on scalePlaceboFluticasone Furoate 110 mcg QD
AM iTNSS Day 1-0.47 ± 0.16-0.92 ± 0.16
AM iTNSS Day 2-0.69 ± 0.17-1.01 ± 0.17
AM iTNSS Day 3-0.75 ± 0.18-1.14 ± 0.18
AM iTNSS Day 4-0.96 ± 0.18-1.22 ± 0.18
AM iTNSS Day 5-1.15 ± 0.20-1.45 ± 0.19
AM iTNSS Day 6-1.01 ± 0.20-1.59 ± 0.19
AM iTNSS Day 7-1.17 ± 0.20-1.55 ± 0.19
AM iTNSS Day 8-1.38 ± 0.20-1.61 ± 0.20
AM iTNSS Day 9-1.47 ± 0.20-1.66 ± 0.20
AM iTNSS Day 10-1.31 ± 0.21-1.78 ± 0.21
AM iTNSS Day 11-1.48 ± 0.22-1.66 ± 0.21
AMiTNSS Day 12-1.52 ± 0.22-1.86 ± 0.21
AM iTNSS Day 13-1.48 ± 0.22-1.83 ± 0.21
AM iTNSS Day 14-1.72 ± 0.21-1.95 ± 0.20
AM iTNSS Day 15-1.54 ± 0.21-1.92 ± 0.21
AM iTNSS Day 16-1.56 ± 0.21-1.99 ± 0.21
AM iTNSS Day 17-1.64 ± 0.22-2.20 ± 0.22
AM iTNSS Day 18-1.75 ± 0.21-2.21 ± 0.21
AM iTNSS Day 19-1.70 ± 0.21-2.33 ± 0.21
AM iTNSS Day 20-1.89 ± 0.22-2.11 ± 0.21
AM iTNSS Day 21-1.97 ± 0.22-2.26 ± 0.22
AM iTNSS Day 22-1.73 ± 0.22-2.32 ± 0.22
AM iTNSS Day 23-1.80 ± 0.23-2.27 ± 0.22
AM iTNSS Day 24-1.93 ± 0.23-2.40 ± 0.22
AM iTNSS Day 25-1.93 ± 0.22-2.36 ± 0.22
AM iTNSS Day 26-2.10 ± 0.23-2.68 ± 0.22
AM iTNSS Day 27-2.01 ± 0.23-2.49 ± 0.22
AM iTNSS Day 28-1.96 ± 0.28-2.62 ± 0.26
rTNSS Day 1-0.71 ± 0.16-0.93 ± 0.15
rTNSS Day 2-0.91 ± 0.16-1.17 ± 0.16
rTNSS Day 3-1.07 ± 0.17-1.38 ± 0.16
rTNSS Day 4-1.15 ± 0.17-1.43 ± 0.16
rTNSS Day 5-1.22 ± 0.17-1.35 ± 0.17
rTNSS Day 6-1.21 ± 0.19-1.51 ± 0.18
rTNSS Day 7-1.37 ± 0.19-1.66 ± 0.18
rTNSS Day 8-1.58 ± 0.18-1.82 ± 0.18
rTNSS Day 9-1.55 ± 0.20-1.92 ± 0.19
rTNSS Day 10-1.60 ± 0.20-2.06 ± 0.19
rTNSS Day 11-1.65 ± 0.20-1.96 ± 0.20
rTNSS Day 12-1.81 ± 0.19-2.14 ± 0.19
rTNSS Day 13-1.87 ± 0.20-2.12 ± 0.20
rTNSS Day 14-1.83 ± 0.20-2.17 ± 0.20
rTNSS Day 15-1.70 ± 0.20-2.11 ± 0.20
rTNSS Day 16-1.82 ± 0.20-2.38 ± 0.20
rTNSS Day 17-1.94 ± 0.21-2.53 ± 0.20
rTNSS Day 18-2.21 ± 0.20-2.51 ± 0.20
rTNSS Day 19-1.99 ± 0.20-2.44 ± 0.20
rTNSS Day 20-2.16 ± 0.20-2.47 ± 0.20
rTNSS Day 21-2.12 ± 0.21-2.54 ± 0.20
rTNSS Day 22-2.01 ± 0.21-2.47 ± 0.21
rTNSS Day 23-1.99 ± 0.21-2.30 ± 0.20
rTNSS Day 24-2.12 ± 0.21-2.60 ± 0.20
rTNSS Day 25-2.28 ± 0.22-2.44 ± 0.21
rTNSS Day 26-2.25 ± 0.22-2.57 ± 0.21
rTNSS Day 27-2.23 ± 0.22-2.51 ± 0.21
rTNSS Day 28-1.93 ± 0.28-2.58 ± 0.26
AM rTNSS Day 1-0.70 ± 0.18-1.02 ± 0.17
AM rTNSS Day 2-0.97 ± 0.18-1.20 ± 0.17
AM rTNSS Day 3-1.12 ± 0.18-1.37 ± 0.18
AM rTNSS Day 4-1.11 ± 0.18-1.45 ± 0.18
AM rTNSS Day 5-1.33 ± 0.19-1.48 ± 0.18
AM rTNSS Day 6-1.30 ± 0.20-1.59 ± 0.20
AM rTNSS Day 7-1.28 ± 0.21-1.69 ± 0.20
AM rTNSS Day 8-1.74 ± 0.21-1.85 ± 0.20
AM rTNSS Day 9-1.73 ± 0.21-1.94 ± 0.21
AM rTNSS Day 10-1.65 ± 0.21-2.10 ± 0.20
AM rTNSS Day 11-1.66 ± 0.21-1.96 ± 0.20
AM rTNSS Day 12-1.82 ± 0.21-2.05 ± 0.20
AM rTNSS Day 13-1.87 ± 0.22-2.06 ± 0.21
AM rTNSS Day 14-1.84 ± 0.21-2.14 ± 0.20
AM rTNSS Day 15-1.67 ± 0.22-2.15 ± 0.21
AM rTNSS Day 16-1.75 ± 0.22-2.37 ± 0.21
AM rTNSS Day 17-2.12 ± 0.22-2.62 ± 0.22
AM rTNSS Day 18-2.22 ± 0.21-2.48 ± 0.21
AM rTNSS Day 19-1.83 ± 0.22-2.37 ± 0.21
AM rTNSS Day 20-2.18 ± 0.22-2.42 ± 0.22
AM rTNSS Day 21-2.07 ± 0.22-2.64 ± 0.22
AM rTNSS Day 22-2.02 ± 0.23-2.44 ± 0.22
AM rTNSS Day 23-1.96 ± 0.23-2.17 ± 0.22
AM rTNSS Day 24-2.03 ± 0.23-2.57 ± 0.22
AM rTNSS Day 25-2.22 ± 0.23-2.45 ± 0.22
AM rTNSS Day 26-2.19 ± 0.23-2.59 ± 0.23
AM rTNSS Day 27-2.23 ± 0.23-2.54 ± 0.23
AM rTNSS Day 28-1.82 ± 0.30-2.55 ± 0.27
PM rTNSS Day 1-0.88 ± 0.20-0.97 ± 0.19
PM rTNSS Day 2-0.91 ± 0.18-1.19 ± 0.17
PM rTNSS Day 3-1.10 ± 0.19-1.39 ± 0.19
PM rTNSS Day 4-1.17 ± 0.19-1.42 ± 0.19
PM rTNSS Day 5-1.06 ± 0.19-1.29 ± 0.18
PM rTNSS Day 6-1.13 ± 0.21-1.42 ± 0.20
PM rTNSS Day 7-1.48 ± 0.20-1.64 ± 0.20
PM rTNSS Day 8-1.34 ± 0.20-1.73 ± 0.19
PM rTNSS Day 9-1.49 ± 0.21-1.89 ± 0.20
PM rTNSS Day 10-1.58 ± 0.21-2.07 ± 0.21
PM rTNSS Day 11-1.62 ± 0.22-2.02 ± 0.22
PM rTNSS Day 12-1.86 ± 0.21-2.29 ± 0.21
PM rTNSS Day 13-1.91 ± 0.22-2.18 ± 0.21
PM rTNSS Day 14-1.85 ± 0.23-2.15 ± 0.22
PM rTNSS Day 15-1.78 ± 0.22-2.15 ± 0.21
PM rTNSS Day 16-1.84 ± 0.23-2.33 ± 0.22
PM rTNSS Day 17-1.81 ± 0.22-2.51 ± 0.22
PM rTNSS Day 18-2.22 ± 0.22-2.54 ± 0.23
PM rTNSS Day 19-2.23 ± 0.21-2.53 ± 0.21
PM rTNSS Day 20-2.17 ± 0.21-2.52 ± 0.20
PM rTNSS Day 21-2.19 ± 0.23-2.48 ± 0.22
PM rTNSS Day 22-2.03 ± 0.22-2.53 ± 0.22
PM rTNSS Day 23-2.06 ± 0.23-2.41 ± 0.22
PM rTNSS Day 24-2.25 ± 0.22-2.64 ± 0.21
PM rTNSS Day 25-2.39 ± 0.23-2.42 ± 0.22
PM rTNSS Day 26-2.31 ± 0.23-2.54 ± 0.22
PM rTNSS Day 27-2.25 ± 0.23-2.54 ± 0.22
PM rTNSS Day 28-2.07 ± 0.30-2.68 ± 0.28
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.011 · Mean difference (net): -0.450 · 95% CI -0.80 to -0.10ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.089 · Mean difference (net): -0.325 · 95% CI -0.70 to 0.05ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.052 · Mean difference (net): -0.393 · 95% CI -0.79 to 0.00ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.187 · Mean difference (net): -0.262 · 95% CI -0.65 to 0.13ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.164 · Mean difference (net): -0.298 · 95% CI -0.72 to 0.12ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.008 · Mean difference (net): -0.573 · 95% CI -1.00 to -0.15ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.082 · Mean difference (net): -0.376 · 95% CI -0.80 to 0.05ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.296 · Mean difference (net): -0.231 · 95% CI -0.67 to 0.20ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.383 · Mean difference (net): -0.191 · 95% CI -0.62 to 0.24ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.048 · Mean difference (net): -0.464 · 95% CI -0.92 to -0.00ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.469 · Mean difference (net): -0.172 · 95% CI -0.64 to 0.29ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.151 · Mean difference (net): -0.340 · 95% CI -0.80 to 0.12ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.145 · Mean difference (net): -0.344 · 95% CI -0.81 to 0.12ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.297 · Mean difference (net): -0.235 · 95% CI -0.68 to 0.21ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.094 · Mean difference (net): -0.380 · 95% CI -0.82 to 0.07ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.064 · Mean difference (net): -0.430 · 95% CI -0.89 to 0.03ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.019 · Mean difference (net): -0.563 · 95% CI -1.03 to -0.09ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.044 · Mean difference (net): -0.457 · 95% CI -0.90 to -0.01ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.007 · Mean difference (net): -0.633 · 95% CI -1.09 to -0.17ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.348 · Mean difference (net): -0.222 · 95% CI -0.69 to 0.24ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.243 · Mean difference (net): -0.281 · 95% CI -0.76 to 0.19ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.014 · Mean difference (net): -0.595 · 95% CI -1.07 to -0.12ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.055 · Mean difference (net): -0.474 · 95% CI -0.96 to 0.01ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.062 · Mean difference (net): -0.464 · 95% CI -0.95 to 0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.079 · Mean difference (net): -0.430 · 95% CI -0.91 to 0.05ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.019 · Mean difference (net): -0.576 · 95% CI -1.06 to -0.10ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.056 · Mean difference (net): -0.480 · 95% CI -0.97 to 0.01ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.018 · Mean difference (net): -0.659 · 95% CI -1.20 to -0.11ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.194 · Mean difference (net): -0.222 · 95% CI -0.56 to 0.1ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.134 · Mean difference (net): -0.263 · 95% CI -0.61 to 0.08ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.091 · Mean difference (net): -0.310 · 95% CI -0.67 to 0.05ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.131 · Mean difference (net): -0.278 · 95% CI -0.64 to 0.08ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.483 · Mean difference (net): -0.130 · 95% CI -0.49 to 0.23ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.137 · Mean difference (net): -0.301 · 95% CI -0.70 to 0.10ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.142 · Mean difference (net): -0.297 · 95% CI -0.69 to 0.10ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.220 · Mean difference (net): -0.245 · 95% CI -0.64 to 0.15ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.081 · Mean difference (net): -0.373 · 95% CI -0.79 to 0.05ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.034 · Mean difference (net): -0.453 · 95% CI -0.87 to -0.04ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.150 · Mean difference (net): -0.314 · 95% CI -0.74 to 0.11ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.111 · Mean difference (net): -0.333 · 95% CI -0.74 to 0.08
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.261 · Mean difference (net): -0.250 · 95% CI -0.69 to 0.19ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.123 · Mean difference (net): -0.342 · 95% CI -0.78 to 0.09ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.056 · Mean difference (net): -0.415 · 95% CI -0.84 to 0.01ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.011 · Mean difference (net): -0.566 · 95% CI -1.00 to -0.13ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.009 · Mean difference (net): -0.590 · 95% CI -1.03 to -0.15ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.175 · Mean difference (net): -0.301 · 95% CI -0.74 to 0.13ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.039 · Mean difference (net): -0.449 · 95% CI -0.87 to -0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.152 · Mean difference (net): -0.315 · 95% CI -0.75 to 0.12ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.063 · Mean difference (net): -0.424 · 95% CI -0.87 to 0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.044 · Mean difference (net): -0.454 · 95% CI -0.90 to -0.01ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.179 · Mean difference (net): -0.312 · 95% CI -0.77 to 0.14ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.034 · Mean difference (net): -0.479 · 95% CI -0.92 to -0.04ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.505 · Mean difference (net): -0.157 · 95% CI -0.62 to 0.31ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.186 · Mean difference (net): -0.317 · 95% CI -0.79 to 0.15ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.234 · Mean difference (net): -0.283 · 95% CI -0.75 to 0.18ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.017 · Mean difference (net): -0.645 · 95% CI -1.17 to -0.12ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.095 · Mean difference (net): -0.320 · 95% CI -0.70 to 0.06ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.236 · Mean difference (net): -0.231 · 95% CI -0.61 to 0.15ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.205 · Mean difference (net): -0.255 · 95% CI -0.65 to 0.14
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.084 · Mean difference (net): -0.343 · 95% CI -0.73 to 0.05ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.475 · Mean difference (net): -0.146 · 95% CI -0.55 to 0.26ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.178 · Mean difference (net): -0.296 · 95% CI -0.73 to 0.14
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.071 · Mean difference (net): -0.406 · 95% CI -0.85 to 0.04ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.621 · Mean difference (net): -0.111 · 95% CI -0.55 to 0.33ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.372 · Mean difference (net): -0.206 · 95% CI -0.66 to 0.25ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.046 · Mean difference (net): -0.452 · 95% CI -0.90 to -0.01ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.183 · Mean difference (net): -0.302 · 95% CI -0.75 to 0.14ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.320 · Mean difference (net): -0.226 · 95% CI -0.67 to 0.22ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.431 · Mean difference (net): -0.188 · 95% CI -0.66 to 0.28
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.191 · Mean difference (net): -0.299 · 95% CI -0.75 to 0.15ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.043 · Mean difference (net): -0.475 · 95% CI -0.94 to -0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.009 · Mean difference (net): -0.619 · 95% CI -1.08 to -0.16ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.040 · Mean difference (net): -0.495 · 95% CI -0.97 to -0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.249 · Mean difference (net): -0.262 · 95% CI -0.71 to 0.18ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.023 · Mean difference (net): -0.536 · 95% CI -1.00 to -0.07ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.321 · Mean difference (net): -0.240 · 95% CI -0.71 to 0.23ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.019 · Mean difference (net): -0.568 · 95% CI -1.04 to -0.09ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.092 · Mean difference (net): -0.419 · 95% CI -0.91 to 0.07ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.404 · Mean difference (net): -0.206 · 95% CI -0.69 to 0.28ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.027 · Mean difference (net): -0.546 · 95% CI -1.03 to -0.06ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.357 · Mean difference (net): -0.227 · 95% CI -0.71 to 0.26ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.114 · Mean difference (net): -0.403 · 95% CI -0.90 to 0.10ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.228 · Mean difference (net): -0.307 · 95% CI -0.81 to 0.19ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.012 · Mean difference (net): -0.725 · 95% CI -1.29 to -0.16ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.643 · Mean difference (net): -0.093 · 95% CI -0.49 to 0.30ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.150 · Mean difference (net): -0.279 · 95% CI -0.66 to 0.10ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.162 · Mean difference (net): -0.291 · 95% CI -0.70 to 0.12ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.242 · Mean difference (net): -0.244 · 95% CI -0.65 to 0.17ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.278 · Mean difference (net): -0.223 · 95% CI -0.63 to 0.18ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.200 · Mean difference (net): -0.282 · 95% CI -0.71 to 0.15ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.456 · Mean difference (net): -0.164 · 95% CI -0.60 to 0.27ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.076 · Mean difference (net): -0.385 · 95% CI -0.81 to 0.04ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.084 · Mean difference (net): -0.396 · 95% CI -0.85 to 0.05ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.040 · Mean difference (net): -0.481 · 95% CI -0.94 to -0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.090 · Mean difference (net): -0.405 · 95% CI -0.87 to 0.06ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.060 · Mean difference (net): -0.432 · 95% CI -0.88 to 0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.252 · Mean difference (net): -0.277 · 95% CI -0.75 to 0.20ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.229 · Mean difference (net): -0.300 · 95% CI -0.79 to 0.19ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.109 · Mean difference (net): -0.373 · 95% CI -0.83 to 0.08ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · Mean difference (net): -0.484 · 95% CI -0.96 to -0.01ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.003 · Mean difference (net): -0.700 · 95% CI -1.17 to -0.23ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.182 · Mean difference (net): -0.326 · 95% CI -0.81 to 0.15ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.194 · Mean difference (net): -0.299 · 95% CI -0.75 to 0.15ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.129 · Mean difference (net): -0.348 · 95% CI -0.80 to 0.10ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.232 · Mean difference (net): -0.292 · 95% CI -0.77 to 0.19ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.042 · Mean difference (net): -0.499 · 95% CI -0.98 to -0.02ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.150 · Mean difference (net): -0.356 · 95% CI -0.84 to 0.13ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.090 · Mean difference (net): -0.398 · 95% CI -0.86 to 0.06ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.909 · Mean difference (net): -0.028 · 95% CI -0.52 to 0.46ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.354 · Mean difference (net): -0.233 · 95% CI -0.73 to 0.26ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.245 · Mean difference (net): -0.290 · 95% CI -0.78 to 0.20ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.
  • Placebo vs Fluticasone Furoate 110 mcg QD · ANCOVA · p = 0.038 · Mean difference (net): -0.601 · 95% CI -1.17 to -0.03ANCOVA method was used adjusting for baseline rTNSS, country, age, and gender, in addition to treatment effect.

Adverse events

Collected over AEs were collected from screening up to 32 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/173 (0%)0/173 (0%)65/173 (37.6%)
Fluticasone Furoate 110mcg QD0/179 (0%)0/179 (0%)61/179 (34.1%)
Most frequent other events
Showing 10 of 96
Most frequent other events
EventPlaceboFluticasone Furoate 110mcg QD
HeadacheNervous system disorders23/17312/179
NasopharyngitisInfections and infestations8/1738/179
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders1/1735/179
DiarrhoeaGastrointestinal disorders0/1735/179
Upper respiratory tract infectionInfections and infestations4/1731/179
EpistaxisRespiratory, thoracic and mediastinal disorders4/1734/179
Sinus headacheNervous system disorders3/1732/179
Neck painMusculoskeletal and connective tissue disorders3/1730/179
Pain in extremityMusculoskeletal and connective tissue disorders3/1730/179
DysmenorrhoeaReproductive system and breast disorders3/1731/179

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboFluticasone Furoate 110 mcg QDTotal
Mean45.0 ± 14.6646.6 ± 16.7745.8 ± 15.77
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFluticasone Furoate 110 mcg QDTotal
Female122125247
Male5154105
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboFluticasone Furoate 110 mcg QDTotal
American Indian or Alaska Native011
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American6410
White163169332
More than one race347
Unknown or Not Reported000
08

Study locations

53 sites
  • GSK Investigational Site
    Beverly Hills, California 90212, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Mission Viejo, California 92691, United States
  • GSK Investigational Site
    San Diego, California 92120, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    Santa Barbara, California 93105, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Englewood, Colorado 80112, United States
  • GSK Investigational Site
    Fort Collins, Colorado 80526, United States
  • GSK Investigational Site
    Woodstock, Georgia 30188, United States
  • GSK Investigational Site
    Chicago, Illinois 60637, United States
  • GSK Investigational Site
    Evansville, Indiana 47713, United States
  • GSK Investigational Site
    Louisville, Kentucky 40207, United States
  • GSK Investigational Site
    Covington, Louisiana 70433, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71104, United States
  • GSK Investigational Site
    Bangor, Maine 04401, United States
  • GSK Investigational Site
    Baltimore, Maryland 21236, United States
  • GSK Investigational Site
    Rockville, Maryland 20850, United States
  • GSK Investigational Site
    Novi, Michigan 48375, United States
  • GSK Investigational Site
    Ypsilanti, Michigan 48197, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55402, United States
  • GSK Investigational Site
    Mount Laurel, New Jersey 08054, United States
  • GSK Investigational Site
    Liverpool, New York 13088, United States
  • GSK Investigational Site
    Rochester, New York 14618, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    North Olmsted, Ohio 44070, United States
  • GSK Investigational Site
    Lake Oswego, Oregon 97035, United States
  • GSK Investigational Site
    Portland, Oregon 97213, United States
  • GSK Investigational Site
    Easton, Pennsylvania 18042, United States
  • GSK Investigational Site
    Palmyra, Pennsylvania 17078, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • GSK Investigational Site
    Upland, Pennsylvania 19013, United States
  • GSK Investigational Site
    Charleston, South Carolina 29407, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Germantown, Tennessee 38138, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37922, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84102, United States
  • GSK Investigational Site
    Kelowna, British Columbia V1Y 9L8, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • GSK Investigational Site
    Québec, G1V 4M6, Canada
  • GSK Investigational Site
    Litomerice, 412 01, Czechia
  • GSK Investigational Site
    Olomouc, 775 25, Czechia
  • GSK Investigational Site
    Tabor, 390 19, Czechia
  • GSK Investigational Site
    Kassel, Hessen 34117, Germany
  • GSK Investigational Site
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30159, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Hamburg, 20249, Germany
  • GSK Investigational Site
    Larvik, N-3256, Norway
  • GSK Investigational Site
    Nesttun, N-5227, Norway
  • GSK Investigational Site
    Bucuresti, Romania
  • GSK Investigational Site
    Deva, 2700, Romania
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2005 to primary completion in Feb 2006, 6 months.

Results were first posted in Mar 2018, 12 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2005
First posted
Jul 6, 2005
StartActual
Jul 11, 2005
Primary completionActual
Feb 9, 2006
CompletionActual
Feb 9, 2006
Results first posted
Mar 13, 2018
Last update
Mar 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00117325
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 6, 2005
Start date
Jul 11, 2005
Primary completion
Feb 9, 2006
Completion
Feb 9, 2006
Results posted
Mar 13, 2018
Last update
Mar 13, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion